Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components; and Requirements for Donor Testing, Donor Notification, and “Lookback”, 123 [E5-8134]
Download as PDF
<![CDATA[
123
Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
210 and 211
Annual Frequency
per Response
285
Total Annual
Responses
1
Hours per
Response
285
Total Hours
.25
Total
71.25
71.25
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
OMB control number 0910–0116. The
approval expires on December 31, 2008.
A copy of the supporting statement for
this information collection is available
on the Internet at https://www.fda.gov/
ohrms/dockets.
ADDRESSES: Comments may be
submitted electronically at the TRWG
Web site: https://www.cancer.gov/trwg/.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
Food and Drug Administration
[FR Doc. E5–8134 Filed 12–30–05; 8:45 am]
The National Cancer Institute is
committed to speeding the development
of new diagnostic tests, cancer
treatments, and other interventions that
benefit people with cancer and people
at risk for cancer. Such development
relies on strong translational research
collaborations between basic and
clinical scientists to generate novel
approaches. Currently, NCI supports a
variety of projects that build this bridge
between basic science and patient care.
Over the next year, the Translational
Research Working Group (TRWG) will
review NCI’s current intramural and
extramural translational research
portfolio (within the scope of the TRWG
mission), facilitate broad community
input, invite public comment, and
recommend ways to improve and
integrate efforts. The ultimate goal is to
accelerate progress toward improving
the health of the nation and cancer
patient outcomes.
[FR Doc. E5–8113 Filed 12–30–05; 8:45 am]
BILLING CODE 4160–01–S
BILLING CODE 4160–01–S
[Docket No. 2005N–0220]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Current Good Manufacturing Practices
and Related Regulations for Blood and
Blood Components; and Requirements
for Donor Testing, Donor Notification,
and ‘‘Lookback’’
AGENCY:
Food and Drug Administration,
HHS.
rmajette on DSK29S0YB1PROD with NOTICES6
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Current Good Manufacturing Practices
and Related Regulations for Blood and
Blood Components; and Requirements
for Donor Testing, Donor Notification,
and ‘Lookback’’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 24, 2005 (70
FR 61447), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
VerDate Mar<15>2010
15:46 Nov 10, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Health
Translational Research Working Group
Public Comment Period
AGENCY: National Cancer Institute (NCI),
National Institutes of Health (NIH),
Department of Health and Human
Services (DHHS).
ACTION: Request for public comment.
SUMMARY: The Translational Research
Working Group (TRWG), a broad panel
including advocates, researchers from
academia, industry representatives, and
government officials, was established in
early 2005 to evaluate the status of the
National Cancer Institute’s (NCI)
intramural and extramural investment
in translational research in order to
develop recommendations on ways to
coordinate and optimally integrate
activities. The TRWG is also charged
with developing implementation
strategies that will enable the scientific
community and NCI leadership to
appropriately prioritize its translational
research opportunities.
Recommendations will be made to the
National Cancer Advisory Board by
early 2007. To assist in its future
planning efforts, TRWG is asking public
stakeholders in the translational
research enterprise for feedback on
some of the key questions facing the
panel and insights on how to proceed.
DATES: The TRWG public comment
period will run from December 20, 2005
to January 20, 2006.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Background
Request for Comments
To better understand the different
viewpoints in the cancer research
community, and to develop and reflect
a common understanding about the
challenges and opportunities in
translational research, TRWG seeks
input on six important areas:
• Barriers to/Incentives for
Translational Research.
• Prioritization.
• Funding.
• System Organization.
• Facilities/Technologies.
• Manpower/Training.
Dated: December 22, 2005.
Ernest Hawk,
Director, Office of Centers, Training and
Resources, National Cancer Institute,
National Institutes of Health.
[FR Doc. 05–24687 Filed 12–30–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\03JAN1.SGM
03JAN1
]]>Agencies
[Federal Register Volume 71, Number 1 (Tuesday, January 3, 2006)]
[Notices]
[Page 123]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8134]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0220]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Current Good Manufacturing Practices
and Related Regulations for Blood and Blood Components; and
Requirements for Donor Testing, Donor Notification, and ``Lookback''
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Current Good Manufacturing
Practices and Related Regulations for Blood and Blood Components; and
Requirements for Donor Testing, Donor Notification, and `Lookback'''
has been approved by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-4659.
SUPPLEMENTARY INFORMATION: In the Federal Register of October 24, 2005
(70 FR 61447), the agency announced that the proposed information
collection had been submitted to OMB for review and clearance under 44
U.S.C. 3507. An agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it displays
a currently valid OMB control number. OMB has now approved the
information collection and has assigned OMB control number 0910-0116.
The approval expires on December 31, 2008. A copy of the supporting
statement for this information collection is available on the Internet
at https://www.fda.gov/ohrms/dockets.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5-8134 Filed 12-30-05; 8:45 am]
BILLING CODE 4160-01-S
